KRYS (KRYS) Stock Analysis
Verdict: BUY
High-margin VYJUVEK scaling and zero debt provide a floor, but aggressive insider selling and a recent revenue miss suggest a cooling period.
Investment score: 68/100
Krystal Biotech is transitioning from a clinical-stage firm to a profitable cash-flow machine. While the recent revenue miss caused a sharp sell-off, the underlying fundamentals—specifically the 9.46 current ratio and lack of debt—remain elite for the biotech sector.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| SMMT | -11.65 | 16.11 | 0.00 | -11.69 | — | 0.00 |
| APGE | -30.97 | 7.44 | 0.00 | -28.80 | — | 0.00 |
| HALO | 28.17 | 44.25 | 6.47 | 18.58 | — | 0.23 |
| CYTK | -11.19 | -11.40 | 89.90 | -14.53 | — | -7.84 |
| IONS | -15.75 | 20.50 | 10.36 | 2.57 | — | -0.65 |